Rigel Pharmaceuticals
RIGL
159 hedge funds and large institutions have $433M invested in Rigel Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 73 increasing their positions, 48 reducing their positions, and 47 closing their positions.
61% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $1.41M
52% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 48
2.27% less ownership
Funds ownership: 88.92% → 86.65% (-2.3%)
18% less funds holding
Funds holding: 193 → 159 (-34)
37% less capital invested
Capital invested by funds: $691M → $433M (-$258M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
64% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 47
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$14.9M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$9.74M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.81M |
| 4 |
Two Sigma Investments
New York
|
+$4.52M |
| 5 |
BlackRock
New York
|
+$3.52M |
Top Sellers
| 1 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$12.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$9.75M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.28M |
| 4 |
Goldman Sachs
New York
|
-$7.82M |
| 5 |
Jane Street
New York
|
-$6.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
201
Aster Capital Management
Dubai,
United Arab Emirates
| – | -$5.7K | -133 | Closed |
|
|
CIAM
202
Caitong International Asset Management
Hong Kong
| – | -$5.35K | -125 | Closed |
|
|
CMBA
203
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$4.92K | -115 | Closed |
|
|
CCM
204
Chilton Capital Management
Houston,
Texas
| – | -$2.01K | -47 | Closed |
|
205
Daiwa Securities Group
Tokyo,
Japan
| – | -$2K | -40 | Closed |
|
|
AAP
206
Arax Advisory Partners
Denver,
Colorado
| – | -$43 | -1 | Closed |
|
RIGL Hedge Fund Activity: Q1 2026 in Review
159 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2026, worth a combined $433M — down 37% from $691M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of RIGL and 17 opened new positions — a net loss of 30 holders — while 48 trimmed existing stakes and 73 added.
The largest buyer was Armistice Capital, adding an estimated $14.9M. The largest seller was Hillsdale Investment Management, exiting entirely with an estimated $12.1M sold.
- 159 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2026, down from 193 in Q4 2025.
- Funds reported $433M of Rigel Pharmaceuticals stock for Q1 2026, down 37% quarter-over-quarter.
- 17 funds opened new Rigel Pharmaceuticals positions in Q1 2026 and 47 closed out, a net change of -30 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2026 was Armistice Capital, an estimated $14.9M added.
- The largest Rigel Pharmaceuticals seller in Q1 2026 was Hillsdale Investment Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2026.